{"id":"oravescent-fentanyl-ovf","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OraVescent fentanyl uses an effervescent tablet technology that creates CO₂ bubbles in the mouth, increasing surface area contact with buccal mucosa and accelerating fentanyl absorption compared to standard oral formulations. This mechanism allows fentanyl—a mu-opioid receptor agonist—to reach therapeutic levels more rapidly, making it suitable for breakthrough pain management. The formulation bypasses first-pass hepatic metabolism by utilizing transmucosal absorption.","oneSentence":"OraVescent fentanyl is a rapid-onset opioid agonist delivered via an effervescent oral formulation that enhances buccal absorption of fentanyl for fast pain relief.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:52.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breakthrough pain in opioid-tolerant cancer patients"}]},"trialDetails":[{"nctId":"NCT00105287","phase":"PHASE3","title":"Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients","status":"COMPLETED","sponsor":"Cephalon","startDate":"2005-01","conditions":"Pain, Cancer","enrollment":100},{"nctId":"NCT00105937","phase":"PHASE3","title":"OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients","status":"COMPLETED","sponsor":"Cephalon","startDate":"2004-04","conditions":"Pain, Cancer","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OraVescent fentanyl (OVF)","genericName":"OraVescent fentanyl (OVF)","companyName":"Cephalon","companyId":"cephalon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OraVescent fentanyl is a rapid-onset opioid agonist delivered via an effervescent oral formulation that enhances buccal absorption of fentanyl for fast pain relief. Used for Breakthrough pain in opioid-tolerant cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}